Bromobenzenes

Sodium octanoate, 96%

CAS: 1984-06-1 MDL Number: MFCD00058511

4-Bromobenzenesulfinic acid sodium salt dihydrate, 97%

CAS: 175278-64-5 Molecular Formula: C6H4BrO2S Molecular Weight (g/mol): 220.06 MDL Number: MFCD00210139 InChI Key: QBLQHDHWTVMHRH-UHFFFAOYSA-M Synonym: sodium 4-bromobenzenesulfinate dihydrate,4-bromobenzenesulfinic acid sodium salt dihydrate,sodium 4-bromobenzene-1-sulphinate dihydrate,acmc-209e9v,c6h4bro2s.na.2h2o,sodium 4-bromophenylsulfinate dihydrate,sodium 4-bromobenzenesulfinate, dihydrate,sodium 4-bromanylbenzenesulfinate dihydrate,4-bromobenzenesulfonic acid sodium salt 2-hydrate,sodium 4-bromobenzene-1-sulfinate-water 1/1/2 PubChem CID: 23683129 IUPAC Name: sodium;4-bromobenzenesulfinate;dihydrate SMILES: [O-]S(=O)C1=CC=C(Br)C=C1

1-Bromo-4-(4-bromophenyl)naphthalene 97.0+%, TCI America™

CAS: 952604-26-1 Molecular Formula: C16H10Br2 Molecular Weight (g/mol): 362.064 InChI Key: APZXILAQCHOANP-UHFFFAOYSA-N PubChem CID: 57816069 IUPAC Name: 1-bromo-4-(4-bromophenyl)naphthalene SMILES: C1=CC=C2C(=C1)C(=CC=C2Br)C3=CC=C(C=C3)Br

Medchemexpress LLC HY-101379A 5mg Medchemexpress, 8-Bromo-cGMP (sodium) CAS:51116-01-9 Purity:>98%

Small and Specialty Supplier Partner
Small and/or specialty supplier based on Federal laws and SBA requirements.
Learn More

Medchemexpress, HY-101379A 5mg 8-Bromo-cGMP (sodium) CAS:51116-01-9 8-Bromo-cGMP sodium, a membrane-permeable analogue of cGMP, is a PKG (protein kinase G) activator and significantly inhibits Ca2+ macroscopic currents and impairs insulin release stimulated with high K+. 8-Bromo-cGMP sodium has antinociceptive effects. Purity:>98% Medchemexpress has over 10000 novel life-science reagents, reference compounds, APIs and natural compounds for laboratory and scientific use. Other quantity can also be offered.

Medchemexpress LLC (2S)-2-[[3-cyclobutyl-5-(3,4,5-trifluorophenoxy)imidazo[4,5-b]pyridin-2-yl]methylamino]propanamide | 1233231-30-5 | 98.3% | 419.4 g/mol | C20H20F3N5O2 | 10MG

Small and Specialty Supplier Partner
Small and/or specialty supplier based on Federal laws and SBA requirements.
Learn More

DSP-2230 (ANP-230) is an orally active small-molecule inhibitor of voltage-gated sodium channels, developed for research into neuropathic pain and sodium-channel pharmacology. It is used in both in vitro and in vivo studies to evaluate inhibition of Nav1.7, Nav1.8, and Nav1.9 and to probe analgesic mechanisms. The compound is supplied as a high-purity research reagent with good solubility in DMSO.

Medchemexpress LLC (2S)-2-[[3-cyclobutyl-5-(3,4,5-trifluorophenoxy)imidazo[4,5-b]pyridin-2-yl]methylamino]propanamide | 1233231-30-5 | 98.3% | 419.4 g/mol | C20H20F3N5O2 | 100MG

Small and Specialty Supplier Partner
Small and/or specialty supplier based on Federal laws and SBA requirements.
Learn More

DSP-2230 (ANP-230) is an orally active small-molecule inhibitor of voltage-gated sodium channels with activity against Nav1.7, Nav1.8, and Nav1.9. It is commonly used in preclinical research on neuropathic pain and sodium channel pharmacology, and is supplied at research-grade purity for in vitro and in vivo studies.

• Inhibits Nav1.7, Nav1.8, and Nav1.9 with reported IC50s of 7.1 μM, 11.4 μM, and 6.7 μM respectively.
• High purity suitable for research use (≈98.3%).
• Small-molecule structure with molecular weight 419.4 g/mol.
• Soluble in DMSO for assay preparation.
• Available in multiple pack sizes to support dose-ranging and scaling studies.

Medchemexpress LLC (2S)-2-[[3-cyclobutyl-5-(3,4,5-trifluorophenoxy)imidazo[4,5-b]pyridin-2-yl]methylamino]propanamide | 1233231-30-5 | 98.3% | 419.4 g/mol | C20H20F3N5O2 | 50MG

Small and Specialty Supplier Partner
Small and/or specialty supplier based on Federal laws and SBA requirements.
Learn More

DSP-2230 (ANP-230) is an orally active inhibitor of voltage-gated sodium channels with activity against Nav1.7, Nav1.8, and Nav1.9. It is used in preclinical research to evaluate analgesic effects and sodium channel modulation in models of neuropathic pain. The compound is supplied as a solid with high purity and documented solubility and storage recommendations for both in vitro and in vivo applications.

• Orally active inhibitor of Nav1.7, Nav1.8, and Nav1.9.
• Suitable for in vitro and in vivo studies, with DMSO solubility ≥100 mg/mL.
• High purity suitable for research use.
• Supplied as a solid powder with recommended cold storage to maintain stability.
• Documented molecular weight and formula support analytical characterization.

Medchemexpress LLC (2S)-2-[[3-cyclobutyl-5-(3,4,5-trifluorophenoxy)imidazo[4,5-b]pyridin-2-yl]methylamino]propanamide | 1233231-30-5 | 98.3% | 419.4 g/mol | C20H20F3N5O2 | 25MG

Small and Specialty Supplier Partner
Small and/or specialty supplier based on Federal laws and SBA requirements.
Learn More

DSP-2230 (ANP-230) is an orally active voltage-gated sodium channel inhibitor used in preclinical research to modulate Nav1.7, Nav1.8, and Nav1.9 activity and to evaluate approaches for neuropathic pain. The compound is supplied as a solid with characterized solubility profiles and storage recommendations for laboratory use only.

• Inhibits Nav1.7, Nav1.8, and Nav1.9 with reported IC50s of 7.1 μM, 11.4 μM, and 6.7 μM respectively.
• Reported purity 98.33%.
• Soluble in DMSO at ≥100 mg/mL; multiple in vivo formulation protocols with solubility ≥2.25 mg/mL are provided.
• Powder stability: -20°C for up to 3 years; solution stability conditions are reported.
• Intended for preclinical studies of sodium channel pharmacology and neuropathic pain models.

Sigma Aldrich 3-chloro-2-hydroxypropanesulfonic acid sodium salt

MilliporeSigma Sigma Organics products encompass a wide range of quality reagents, solvents, catalysts, and building blocks for organic synthesis. From benchtop discovery to process development and scale-up, Sigma Organics solutions are built to meet the needs of synthetic chemists.